ACOG“妊娠期慢性高血压指南(2019)”解读

2019-09-02 中国实用妇科与产科杂志.2019,35(9):1014-1018.

妊娠期慢性高血压的发病率为0.9%~1.5%,从2000年到2009年,妊娠期慢性高血压的发病率增加了67%,其中非洲裔美国孕妇的增幅最大(87%),这种增长主要是由于孕妇肥胖和年龄增加所造成的。妊娠期慢性高血压导致孕产妇、胎儿和新生儿发病率和死亡率显著升高。2019 年ACOG 发布了“ 妊娠期慢性高血压指南(2019)”。该指南的目的是澄清用于定义和诊断妊娠前或妊娠期间慢性高血压的标准,以回顾

中文标题:

ACOG“妊娠期慢性高血压指南(2019)”解读

发布机构:

发布日期:

2019-09-02

简要介绍:

妊娠期慢性高血压的发病率为0.9%~1.5%,从2000年到2009年,妊娠期慢性高血压的发病率增加了67%,其中非洲裔美国孕妇的增幅最大(87%),这种增长主要是由于孕妇肥胖和年龄增加所造成的。妊娠期慢性高血压导致孕产妇、胎儿和新生儿发病率和死亡率显著升高。2019 年ACOG 发布了“ 妊娠期慢性高血压指南(2019)”。该指南的目的是澄清用于定义和诊断妊娠前或妊娠期间慢性高血压的标准,以回顾慢性高血压对妊娠的影响,并评估现有的管理证据。其修订的目的是基于新的研究数据及相关的病理生理学和药理学考虑,为妊娠期慢性高血压提供一种合理的治疗方法。

作者: 重庆医科大学附属第一医院妇产科 彭威 漆洪波

 

拓展指南:妊娠相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=ACOG“妊娠期慢性高血压指南(2019)”解读)] GetToolGuiderByIdResponse(projectId=1, id=d8ed31c001e89ad2, title=ACOG“妊娠期慢性高血压指南(2019)”解读, enTitle=, guiderFrom=中国实用妇科与产科杂志.2019,35(9):1014-1018., authorId=null, author=, summary=妊娠期慢性高血压的发病率为0.9%~1.5%,从2000年到2009年,妊娠期慢性高血压的发病率增加了67%,其中非洲裔美国孕妇的增幅最大(87%),这种增长主要是由于孕妇肥胖和年龄增加所造成的。妊娠期慢性高血压导致孕产妇、胎儿和新生儿发病率和死亡率显著升高。2019 年ACOG 发布了“ 妊娠期慢性高血压指南(2019)”。该指南的目的是澄清用于定义和诊断妊娠前或妊娠期间慢性高血压的标准,以回顾, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Sep 02 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>妊娠期慢性高血压的发病率为0.9%~1.5%,从2000年到2009年,妊娠期慢性高血压的发病率增加了67%,其中非洲裔美国孕妇的增幅最大(87%),这种增长主要是由于孕妇肥胖和年龄增加所造成的。妊娠期慢性高血压导致孕产妇、胎儿和新生儿发病率和死亡率显著升高。2019 年ACOG 发布了“ 妊娠期慢性高血压指南(2019)”。该指南的目的是澄清用于定义和诊断妊娠前或妊娠期间慢性高血压的标准,以回顾慢性高血压对妊娠的影响,并评估现有的管理证据。其修订的目的是基于新的研究数据及相关的病理生理学和药理学考虑,为妊娠期慢性高血压提供一种合理的治疗方法。 </P>作者: 重庆医科大学附属第一医院妇产科 彭威 漆洪波 <P> </P>拓展指南:<strong>与<font color=red>妊娠</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=6fdfd1c001e858ea" title="2019 共识建议:减重手术后妊娠,围产期、产前和产后护理" target=_blank>2019 共识建议:减重手术后妊娠,围产期、产前和产后护理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8ff0f1c001e836d3" title="妊娠合并心脏病围麻醉期中国专家临床管理共识" target=_blank>妊娠合并心脏病围麻醉期中国专家临床管理共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=4e5b41c001e761fd" title="剖宫产术后瘢痕子宫孕妇中期妊娠引产的专家共识" target=_blank>剖宫产术后瘢痕子宫孕妇中期妊娠引产的专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=94b981c001e722e9" title="2019 USPSTF建议声明:妊娠女性HBV感染的筛查" target=_blank>2019 USPSTF建议声明:妊娠女性HBV感染的筛查</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=bf1c91c001e69970" title="2019 NCCN临床实践指南:妊娠滋养细胞肿瘤(2019.V2)" target=_blank>2019 NCCN临床实践指南:妊娠滋养细胞肿瘤(2019.V2)</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E5%A6%8A%E5%A8%A0" target=_blank>有关妊娠更多指南</a></ul>, tagList=[TagDto(tagId=85391, tagName=妊娠期慢性高血压)], categoryList=[CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10661, appHits=399, showAppHits=35, pcHits=8507, showPcHits=2756, likes=74, shares=39, comments=3, approvalStatus=1, publishedTime=Tue Sep 10 22:36:41 CST 2019, publishedTimeString=2019-09-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Sep 10 22:36:41 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 23:49:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=ACOG“妊娠期慢性高血压指南(2019)”解读)])
ACOG“妊娠期慢性高血压指南(2019)”解读
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1233565, encodeId=18ee123356503, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Wed Jul 20 10:00:13 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954670, encodeId=48249546e0f4, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:29:09 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804715, encodeId=742f804e1532, content=学习了,收益很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15875242542, createdName=147c3b86m51暂无昵称, createdTime=Mon Jul 27 10:39:50 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2022-07-20 李曌

    点赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1233565, encodeId=18ee123356503, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Wed Jul 20 10:00:13 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954670, encodeId=48249546e0f4, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:29:09 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804715, encodeId=742f804e1532, content=学习了,收益很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15875242542, createdName=147c3b86m51暂无昵称, createdTime=Mon Jul 27 10:39:50 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    资料好好,但无法分享,遗憾!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1233565, encodeId=18ee123356503, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210708/bf9e13628a7540c8bdded17349a84dcd/7595f30ec58b494c9ad54fa09af51de8.jpg, createdBy=3c925261712, createdName=李曌, createdTime=Wed Jul 20 10:00:13 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954670, encodeId=48249546e0f4, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:29:09 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804715, encodeId=742f804e1532, content=学习了,收益很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15875242542, createdName=147c3b86m51暂无昵称, createdTime=Mon Jul 27 10:39:50 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2020-07-27 147c3b86m51暂无昵称

    学习了,收益很多

    0